FDA WARNING LETTERS

Analysis and Guidance

Jeanne Moldenhauer

www.pda.org/bookstore
FDA Warning Letters

Analysis and Guidance

Jeanne Moldenhauer

To order this book, please visit: go.pda.org/FWLAG

PDA
Bethesda, MD, USA

DHI Publishing, LLC
River Grove, IL, USA

www.pda.org/bookstore
CONTENTS

About the Author ix

1 Introduction 1
References 3

2 Why can FDA Inspect my Plant? 5
Responsibilities of the FDA 5
  Review of New Products 6
  Monitoring Products on the Market 6
  Development of Standards and Regulations 7
  Research Activities 7
  Enforcement Activities 7
The Food, Drug and Cosmetic Act 8
The Bill of Rights 9
Constitutional Challenges to the Authority to Inspect Facilities 9
FDA Responsibilities 11
FDA Inspections 12
  FDA Investigators 14
The FDA Investigator’s Role During an Inspection 14
  Regulatory Notes 14
iv

FDA’s Approach to Inspections

3

Objectives of Systems-Based Drug Inspections
Strategy
Systems for Audit During Inspection
Quality System
Facilities and Equipment System
Materials System
The Production System
The Packaging and Labeling System
The Laboratory Control System
Inspection Options
Full Inspection Option
Abbreviated Inspection Option
Selection of the Systems to be Inspected
Product Classes
Other Types of Inspections
Compliance Inspections
State of Control
Out-of-Control
Contents

References 36
Attachment 1: FDA Compliance Program Guidance Manual 7356.002 37

4 Evaluating Your Facility for Compliance 67
Who Should Perform Assessments 68
Typical Assessment Procedures 68
Audit Preparation 68
During the Audit 70
Completing the Assessment 70
Assessment Report 70
Assessment Follow-Up 71
Retention of Assessment Reports 71
Example of an Audit Checklist 72

5 Overview of Warning Letter Observations 101
Subpart A—General Provisions 101
  §211.1 Scope 101
  §211.3 Definitions 102
Subpart B—Organization and Personnel 102
  §211.22 Responsibilities of the Quality Control Unit 102
  §211.25 Personnel Qualifications 149
  §211.28 Personnel Responsibilities 150
  §211.34 Consultants 152
Subpart C—Buildings and Facilities 152
  §211.42 Design and Construction Features 152
  §211.44 Lighting 168
  §211.46 Ventilation, air filtration, air heating and cooling 168
  §211.48 Plumbing 170
  §211.50 Sewage and refuse 172
  §211.52 Washing and toilet facilities 172
  §211.56 Sanitation 173
  §211.58 Maintenance 176
Subpart D—Equipment 178
  §211.63 Equipment design, size and location 178
  §211.65 Equipment construction 182
  §211.67 Equipment Cleaning and Maintenance 183
  §211.68 Automatic, mechanical and electronic equipment 198
  §211.72 Filters 219
Subpart E—Control of Components and Drug Product Containers and Closures

§211.80 General requirements 220
§211.82 Receipt and storage of untested components, drug product containers, and closures 221
§211.84 Testing and Approval or Rejection of Components, Drug Product Containers, and Closures 222
§211.86 Use of approved components, drug product containers and closures 238
§211.87 Retesting of approved components, drug product containers, and closures 238
§211.89 Rejected components, drug product containers and closures 238
§211.94 Drug product containers and closures 239

Subpart F—Production and Process Controls 240

§211.100 Written Procedures; Deviations 240
§211.101 Charge-in of components 260
§211.103 Calculation of yield 262
§211.105 Equipment identification 262
§211.110 Sampling and testing of in-process materials and drug products 263
§211.111 Time limitations on production 267
§211.113 Control of microbiological contamination 269
§211.115 Reprocessing 282

Subpart G—Packaging and Labeling Control (CFR, 2019) 283

§211.122 Materials examination and criteria 283
§211.125 Labeling issuance 285
§211.130 Packaging and labeling operations 286
§211.132 Tamper-evident packaging requirements for over-the-counter (OTC) human drug products 287
§211.134 Drug product inspection 290
§211.137 Expiration Dating 291

Subpart H—Holding and Distribution 296

§211.142 Warehousing procedures 296
§211.150 Distribution procedures 297

Subpart I—Laboratory Controls 297

§211.160 General Requirements 297
§211.165 Testing and Release for Distribution 318
§211.166 Stability Testing 349
§211.167 Special testing requirements 359
§211.170 Reserve samples 360
Contents

§211.173 Laboratory animals 362
§211.176 Penicillin contamination 362
§211.180 General requirements 363
§211.182 Equipment cleaning and use log 366
§211.184 Component, drug product container, closure, and labeling records 367
§211.186 Master production and control records 368
§211.188 Batch production and control records 371
§211.192 Production Record Review 382
§211.194 Laboratory Records 435
§211.198 Complaint files 452
§212.30 What requirements must my facilities and equipment meet? 456

Other Observations 458
General Comments 462
Access to information during inspection (Limiting Photography) 462
Additional API CGMP guidance 468
Additional guidance on aseptic processing 468
Aseptic processing consultant recommended 468
CGMP Consultant Recommended 468
Data Integrity Remediation 469
Inadequate Control of Manufacturing Processes 469
Labeling and Formulation Concerns 469
Out-of-Specification Test Results 470
Owner’s Responsibilities 470
Process Controls 470
Process Validation 471
Purchase/Shipment of drugs from a manufacturer on FDA Import Alert 66-40 471
Quality Agreement 471
Quality Systems 472
Testing for Glycerin 472
Responsibilities as a Contractor 472
Unkept Facility 472
Repeat Violations at Multiple Sites 473
Receipt of Adulterated Drugs from Contract Manufacturers and Suppliers 473
Use of Bureau Veritas to Conduct Testing of Drug Products 475
Use of Contract Manufacturers 476

References 476